Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2024 > Vol 5, №11 (2024) > Using alternative nicotine products to reduce harm to patients not refusing nicotine consumption. Narrative review

Using alternative nicotine products to reduce harm to patients not refusing nicotine consumption. Narrative review

Maksim L. Maksimov , Marina S. Danilova , Anastasiia A. Shikaleva , Albina A. Zvegintzeva

For citation:


  • Abstract
  • About the Author
  • References

Abstract

Aim. To systematize the data on the problem of patients who do not quit nicotine use and to answer the question: are alternative sources of nicotine delivery significantly less harmful than continuing to smoke traditional cigarettes for smokers who are not motivated to quit? To search for information, the studies were systematized according to the rules for preparing a systematic review according to the PICO requirements: Patients (P) – adults who smoke cigarettes; Intervention (I) – switching from cigarettes to ECs or ESDTs; Comparison (C) – participants who continue to smoke; Outcomes (O) – change in biomarkers of exposure and biomarkers of clinical risk.
Methods. The following keywords were used for the search. The influence of various factors on smoking cessation and relief of symptoms when switching to ECs: randomized controlled trial, smoking cessation, hospitalization, quitting tobacco smoking, quitting smoking, heated tobacco product. Pathogenetic effects of cigarette smoke on the body: cigarette smoke, tobacco products, nicotine delivery devices, cardiovascular system, risk, parameters, reward, cigarette. The following resources were used for the search: Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, ClinicalTrials.gov, Elibrary, Scopus. The obtained materials were entered into Rayyan for systematization and primary analysis. First, duplicate articles were excluded, then articles were excluded by titles and/or abstracts. Editorials, comments, letters, news articles, studies that have not undergone peer review, including conference abstracts, unpublished clinical trials and articles from preprints were excluded from the study.
Results. The analyzed data report that the transition to alternative nicotine delivery systems (ANDS), although not helping to completely quit nicotine, reduces the impact of toxicants on the body of former smokers of classic cigarettes. ANDS contain fewer harmful and potentially harmful substances compared to tobacco smoke and have less cytotoxicity. However, they still contain carcinogenic substances, can cause oxidative stress and inflammation, but to a lesser extent than classic cigarettes. Complete cessation of smoking and nicotine-containing products remains the best option for maintaining health. At the same time, the study showed that not all patients are able to quit nicotine even with counseling and additional therapy, which demonstrates the need for flexible approaches to reduce harm in such patients.
Keywords: electronic nicotine delivery systems, tobacco heating system, alternative nicotine delivery sources, cardiovascular diseases, respiratory diseases, oncological diseases, smoking.

About the Author

Maksim L. Maksimov 1 , Marina S. Danilova 2 , Anastasiia A. Shikaleva 3 , Albina A. Zvegintzeva 4

1 Kazan State Medical Academy – branch of the Russian Medical Academy of Continuous Professional Education, Kazan, Russia; Pirogov Russian National Research Medical University, Moscow, Russia; Russian Medical Academy of Continuous Medical Education, Moscow,

2 Mari State University, Yoshkar-Ola, Russia

3 Kazan State Medical Academy – branch of the Russian Medical Academy of Continuous Professional Education, Kazan, Russia; Kazan State Medical University, Kazan, Russia

4 Kazan State Medical Academy – branch of the Russian Medical Academy of Continuous Professional Education, Kazan, Russia; Republican Clinical Hospital, Kazan, Russia

References

1. Institute of Health Metrics. Global Burden of Disease [database]. Washington, DC: Institute of Health Metrics, 2019 [cited 2023 Jul 17]. Available at: https://extranet.who.int/ncdsmicrodata/index.php/catalog/270
2. Клинические рекомендации. Синдром зависимости от табака, синдром отмены табака у взрослых. 2018.
Clinical guidelines. Tobacco dependence syndrome, tobacco withdrawal syndrome in adults. 2018 (in Russian).
3. Федеральный закон от 23.02.2013 №15-ФЗ «Об охране здоровья граждан от воздействия окружающего табачного дыма и последствий потребления табака».
Federal Law of 23.02.2013 No. 15-FZ «On the Protection of Citizens‘ Health from the Effects of Second-Hand Tobacco Smoke and the Consequences of Tobacco Consumption» (in Russian).
4. Российский статистический ежегодник. 2023: Стат.сб./Росстат. М., 2023.
Russian statistical yearbook. 2023: Stat.sb./Rosstat. Moscow, 2023 (in Russian).
5. Visseren FLJ, Mach F, Smulders YM et al.; ESC Scientific Document Group (2021). 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42(34):3227–337. DOI: 10.1093/eurheartj/ehab484
6. Benowitz NL, Prochaska JJ. Smoking cessation after acute myocardial infarction. JACC 2013;61(5):533-5. DOI: 10.1016/j.jacc.2012.11.017
7. Lang AE. Update on the National Cancer Institute’s Smoking Cessation at Lung Examination Collaboration Trials. Chest 2024;165(6):1302-6. DOI: 10.1016/j.chest.2023.12.016
8. Eisenberg MJ, Grandi SM, Gervais A et al. & ZESCA Investigators. Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: a randomized, placebo-controlled trial. JACC 2013;61(5):524-32. DOI: 10.1016/j.jacc.2012.08.1030
9. Jankowski P, Kosior DA, Sowa P et al. Secondary prevention of coronary artery disease in Poland. Results from the POLASPIRE survey. Cardiol J 2020;27(5):533-40. DOI: 10.5603/CJ.a2020.0072
10. Snaterse M, Deckers JW, Lenzen MJ et al. & EUROASPIRE Investigators. Smoking cessation in European patients with coronary heart disease. Results from the EUROASPIRE IV survey: A registry from the European Society of Cardiology. Int J Cardiol 2018;(258):1-6. DOI: 10.1016/j.ijcard.2018.01.064
11. Streck JM, Rigotti NA, Livingstone-Banks J et al. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev 2024;5(5):CD001837. DOI: 10.1002/14651858.CD001837.
pub4
12. Hartmann–Boyce J, McRobbie H, Butler AR et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev 2021;9(8):CD010216. DOI: 10.1002/14651858.CD010216.pub5
13. Polosa R, Morjaria JB, Prosperini U et al. Health outcomes in COPD smokers using heated tobacco products: a 3-year follow-up. Int Emergency Med 2021;16(3):687-96. DOI: 10.1007/s11739-021-02674-3
14. Бонцевич Р.А., Шершнева А.С., Вовк Я.Р. и др. Хроническая обструктивная болезнь легких: оценка знаний врачей терапевтического профиля. Итоги исследования ASCO-II. Врач. 2020;(7):68-74. DOI: 10.29296/25877305-2020-07-13
Bontsevich R.A., Shershneva A.S., Vovk Ya.R. et al. Chronic obstructive pulmonary disease: assessment of knowledge of physicians of the therapeutic profile. Results of the ASCO-II study. Doctor. 2020;(7):68-74. DOI: 10.29296/25877305-2020-07-13 (in Russian).
15. Бонцевич Р.А., Водяхина А.Я., Умеренков А.А. и др. Бронхиальная астма – фармакоэпидемиологический срез знаний врачей. Итоги исследования «ASSA–III». Вестник современной клинической медицины. 2024;17(2):23-33. DOI: 10.20969/VSKM.2024.17(2).23-33
Bontsevich R.A., Vodakhina A.Ya., Umerenkov A.A., et al. Bronchial asthma – a pharmacoepidemiological cross-section of physicians’ knowledge. Results of the “ASSA–III” study. Bulletin of Contemporary Clinical Medicine. 2024;17(2):23–33. DOI: 10.20969/VSKM.2024. 17(2).23–33 (in Russian).
16. Andreozzi P, Gussoni G, Sesti G et al. Impact of electronic cigarettes (e-cigs) and heat-not-burn/heated tobacco products (HnB/HTP) on asthma and chronic obstructive pulmonary disease: a viewpoint of the Italian Society of Internal Medicine. Intern Emerg Med 2024;(19):1829-37. DOI: 10.1007/s11739-024-03648-x
17. Berlowitz JB, Xie W, Harlow AF et al. E-Cigarette Use and Risk of Cardiovascular Disease: A Longitudinal Analysis of the PATH Study (2013-2019). Circulation 2022;145(20):1557-9. DOI: 10.1161/CIRCULATIONAHA.121.057369
18. Choi S, Lee K, Park SM. Combined Associations of Changes in Noncombustible Nicotine or Tobacco Product and Combustible Cigarette Use Habits With Subsequent Short-Term Cardiovascular Disease Risk Among South Korean Men: A Nationwide Cohort Study. Circulation 2021;144(19):1528-38. DOI: 10.1161/CIRCULATIONAHA.121.054967
19. Benowitz NL. Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis 2003;46(1):91-111. DOI: 10.1016/s0033-0620(03)00087-2. PMID: 12920702
20. Caliri AW, Tommasi S, Besaratinia A. Relationships among smoking, oxidative stress, inflammation, macromolecular damage, and cancer. Mutat Res Rev Mutat Res 2021;(787):108365. DOI: 10.1016/j.mrrev. 2021.108365. Epub 2021 Jan 11. PMID: 34083039; PMCID: PMC8287787
21. Yugar-Toledo C, Rodrigues B, Vilela-Martin J et al. Smoking and Endothelial Dysfunction: An Integrated – Medical and Molecular Review. Med Res Arch 2022;(10). DOI: 10.18103/mra.v10i9.3105
22. Klein J, Diaba-Nuhoho P, Giebe S et al. Regulation of endothelial function by cigarette smoke and next-generation tobacco and nicotine products. Pflugers Arch 2023;475(7):835-44. DOI: 10.1007/s00424-023-02824-w
23. Stephens WE. Comparing the cancer potencies of emissions from vapourised nicotine products including e-cigarettes with those of tobacco smoke. Tobacco control, tobaccocontrol-2017-053808. Advance Online Publication 2017. DOI: 10.1136/tobaccocontrol-2017-053808
24. Chapman F, Sticken ET, Wieczorek R et al. Multiple endpoint in vitro toxicity assessment of a prototype heated tobacco product indicates substantially reduced effects compared to those of combustible cigarette. Toxicol In Vitro 2023;(86):105510. DOI: 10.1016/j.tiv.2022. 105510
25. Münzel T, Hahad O, Kuntic M et al. Effects of tobacco cigarettes, e-cigarettes, and waterpipe smoking on endothelial function and clinical outcomes. Eur Heart J 2020;41(41):4057-70. DOI: 10.1093/eurheartj/ehaa460
26. Lugg ST, Scott A, Parekh D et al. Cigarette smoke exposure and alveolar macrophages: mechanisms for lung disease. Thorax 2022;77(1):94-101. DOI: 10.1136/thoraxjnl-2020-216296
27. Forster M, Fiebelkorn S, Yurteri C et al. Assessment of novel tobacco heating product THP1.0. Part 3: Comprehensive chemical characterisation of harmful and potentially harmful aerosol emissions. Regul Toxicol Pharmacol 2018;(93):14-33. DOI: 10.1016/j.yrtph.2017.10.006
28. Malas M, van der Tempel J, Schwartz R et al. Electronic Cigarettes for Smoking Cessation: A Systematic Review. Nicotine Tob Res 2016;18(10):1926-36. DOI: 10.1093/ntr/ntw119
29. Tan AS, Bigman CA. E-cigarette awareness and perceived harmfulness: prevalence and associations with smoking-cessation outcomes. Am J Prev Med 2014;47(2):141-9. DOI: 10.1016/j.amepre.2014.02.011. Epub 2014 Apr 30. Erratum in: Am J Prev Med 2016;50(5):674-6. DOI: 10.1016/j.amepre.2016.01.006
30. Tattan-Birch H, Hartmann-Boyce J, Kock L et al. Heated tobacco products for smoking cessation and reducing smoking prevalence. Cochrane Database Syst Rev 2022;1(1):CD013790. DOI: 10.1002/14651858.CD013790.pub2
31. Cruz-Jiménez L, Barrientos-Gutiérrez I, Vidaña-Pérez D et al. Heated tobacco product use frequency, smoking quit attempts, and smoking reduction among Mexican adult smokers. Tob Induc Dis 2024;(22). DOI: 10.18332/tid/187576
32. Pasquereau A, Guignard R, Andler R, Nguyen-Thanh V. Electronic cigarettes, quit attempts and smoking cessation: a 6-month follow-up. Addiction 2017;112(9):1620-8. DOI: 10.1111/add.13869
33. Mantey DS, Cooper MR, Loukas A, Perry CL. E-cigarette Use and Cigarette Smoking Cessation among Texas College Students. Am J Health Behav 2017;41(6):750-9. DOI: 10.5993/AJHB.41.6.9
34. Obernolte H, Niehof M, Braubach P et al. Cigarette smoke alters inflammatory genes and the extracellular matrix – investigations on viable sections of peripheral human lungs. Cell Tissue Res 2022;387(2):249-60. DOI: 10.1007/s00441-021-03553-1
35. Титова О.Н., Суховская О.А., Куликов В.Д. Табакокурение и внебольничная пневмония. РМЖ. Медицинское обозрение. 2019;3(9,I):34-7.
Titova O.N., Sukhovskaya O.A., Kulikov V.D. Tobacco smoking and community-acquired pneumonia. RMJ. Medical Review. 2019;3(9,I):34-7 (in Russian).
36. Marinucci L, Coniglio M, Valenti C et al. In Vitro effects of alternative smoking devices on oral cells: Electronic cigarette and heated tobacco product versus tobacco smoke. Arch Oral Biol 2022;144:105550. DOI: 10.1016/j.archoralbio.2022.105550
37. Colombo G, Dalle-Donne I, Orioli M et al. Oxidative damage in human gingival fibroblasts exposed to cigarette smoke. Free Radic Biol Med 2012;52(9):1584-96. DOI: 10.1016/j.freeradbiomed.2012.02.030
38. Zanetti F, Titz B, Sewer A et al. Comparative systems toxicology analysis of cigarette smoke and aerosol from a candidate modified risk tobacco product in organotypic human gingival epithelial cultures: A 3-day repeated exposure study. Food Chem Toxicol 2017;(101):15-35. DOI: 10.1016/j.fct.2016.12.027
39. Ishida M, Sakai C, Kobayashi Y, Ishida T. Cigarette Smoking and Atherosclerotic Cardiovascular Disease. J Atheroscler Thromb 2024;31(3):189-200. DOI: 10.5551/jat.RV22015
40. Seo YS, Park JM, Kim JH, Lee MY. Cigarette Smoke-Induced Reactive Oxygen Species Formation: A Concise Review. Antioxidants (Basel) 2023;12(9):1732. DOI: 10.3390/antiox12091732
41. Giebe S, Hofmann A, Brux M et al. Comparative study of the effects of cigarette smoke versus next generation tobacco and nicotine product extracts on endothelial function. Redox Biol 2021;(47):102150. DOI: 10.1016/j.redox.2021.102150
42. Barua RS, Ambrose JA. Mechanisms of coronary thrombosis in cigarette smoke exposure. Arterioscler Thromb Vasc Biol 2013;33(7):1460-7. DOI: 10.1161/ATVBAHA.112.300154
43. Sevilla-Montero J, Labrousse-Arias D, Fernández-Pérez C et al. Cigarette Smoke Directly Promotes Pulmonary Arterial Remodeling and Kv7.4 Channel Dysfunction. Am J Respir Crit Care Med 2021;203(10):1290-305. DOI: 10.1164/rccm.201911-2238OC
44. Haptonstall KP, Choroomi Y, Moheimani R et al. Differential effects of tobacco cigarettes and electronic cigarettes on endothelial function in healthy young people. Am J Physiol Heart Circ Physiol 2020;319(3):H547-H556. DOI: 10.1152/ajpheart.00307.2020
45. Giebe S, Brux M, Hofmann A et al. Comparative study of the effects of cigarette smoke versus next-generation tobacco and nicotine product extracts on inflammatory biomarkers of human monocytes. Pflugers Arch 2023;475(7):823-33. DOI: 10.1007/s00424-023-02809-9
46. Li X, Wang X, Cui P et al. Comparison of Biomarkers of Exposure in a Controlled Study of Smokers Switched from Conventional Cigarettes to Heated Tobacco Products. Toxics 2023;11(10):816. DOI: 10.3390/toxics11100816
47. Gale N, McEwan M, Hardie G et al. Changes in biomarkers of exposure and biomarkers of potential harm after 360 days in smokers who either continue to smoke, switch to a tobacco heating product or quit smoking. Intern Emerg Med 2022;17(7):2017-30. DOI: 10.1007/s11739-022-03062-1
48. Lüdicke F, Picavet P, Baker G et al. Effects of Switching to the Menthol Tobacco Heating System 2.2, Smoking Abstinence, or Continued Cigarette Smoking on Clinically Relevant Risk Markers: A Randomized, Controlled, Open-Label, Multicenter Study in Sequential Confinement and Ambulatory Settings (Part 2). Nicotine Tob Res 2018;20(2):173-82. DOI: 10.1093/ntr/ntx028
49. Lüdicke F, Picavet P, Baker G et al. Effects of Switching to the Tobacco Heating System 2.2 Menthol, Smoking Abstinence, or Continued Cigarette Smoking on Biomarkers of Exposure: A Randomized, Controlled, Open-Label, Multicenter Study in Sequential Confinement and Ambulatory Settings (Part 1). Nicotine Tob Res 2018;20(2):161-72. DOI: 10.1093/ntr/ntw287
50. McEwan M, Gale N, Ebajemito JK et al. A randomized controlled study in healthy participants to explore the exposure continuum when smokers switch to a tobacco heating product or an E-cigarette relative to cessation. Toxicol Rep 2021;8:994-1001. DOI: 10.1016/j.toxrep.2021.05.003
51. Lüdicke F, Haziza C, Weitkunat R, Magnette J. Evaluation of Biomarkers of Exposure in Smokers Switching to a Carbon-Heated Tobacco Product: A Controlled, Randomized, Open-Label 5-Day Exposure Study. Nicotine Tob Res 2016;18(7):1606-13. DOI: 10.1093/ntr/ ntw022
52. Ansari SM, Hession PS, David M et al. Impact of switching from cigarette smoking to tobacco heating system use on biomarkers of potential harm in a randomized trial. Biomarkers 2024;29(5):298-314. DOI: 10.1080/1354750X.2024.2358318
53. Gale N, McEwan M, Eldridge AC et al. Changes in Biomarkers of Exposure on Switching From a Conventional Cigarette to Tobacco Heating Products: A Randomized, Controlled Study in Healthy Japanese Subjects. Nicotine Tob Res 2019;21(9):1220-7. DOI: 10.1093/ntr/nty104
54. Ogden MW, Marano KM, Jones BA et al. Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: Part 2. Biomarkers of exposure. Biomarkers 2015;20(6-7):391-403. DOI: 10.3109/1354750X.2015.1094134
55. Lüdicke F, Ansari SM, Lama N et al. Effects of Switching to a Heat-Not-Burn Tobacco Product on Biologically Relevant Biomarkers to Assess a Candidate Modified Risk Tobacco Product: A Randomized Trial. Cancer Epidemiol Biomarkers Prev 2019;28(11):1934-43. DOI: 10.1158/1055-9965.EPI-18-0915
56. Lüdicke F, Baker G, Magnette J et al. Reduced Exposure to Harmful and Potentially Harmful Smoke Constituents With the Tobacco Heating System 2.1. Nicotine Tob Res 2017;19(2):168-75. DOI: 10.1093/ntr/ntw164
57. Haziza C, de La Bourdonnaye G, Donelli A et al. Favorable Changes in Biomarkers of Potential Harm to Reduce the Adverse Health Effects of Smoking in Smokers Switching to the Menthol Tobacco Heating System 2.2 for 3 Months (Part 2). Nicotine Tob Res 2020;22(4):549-59. DOI: 10.1093/ntr/ntz084
58. Haziza C, de La Bourdonnaye G, Skiada D et al. Evaluation of the Tobacco Heating System 2.2. Part 8: 5-Day randomized reduced exposure clinical study in Poland. Regul Toxicol Pharmacol 2016;81(Suppl.2):S139-S150. DOI: 10.1016/j.yrtph.2016.11.003
59. Bosilkovska M, Tran CT, de La Bourdonnaye G et al. Exposure to harmful and potentially harmful constituents decreased in smokers switching to Carbon-Heated Tobacco Product. Toxicol Lett. Published online May 5, 2020. DOI: 10.1016/j.toxlet.2020.04.013
60. Tricker AR, Kanada S, Takada K et al. Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System. Part 6: 6-Day randomized clinical trial of a menthol cigarette in Japan. Regul Toxicol Pharmacol 2012;64(Suppl.2):S64-S73. DOI: 10.1016/j.yrtph.2012.08.007
61. Haziza C, de La Bourdonnaye G, Merlet S et al. Assessment of the reduction in levels of exposure to harmful and potentially harmful constituents in Japanese subjects using a novel tobacco heating system compared with conventional cigarettes and smoking abstinence: A randomized controlled study in confinement. Regul Toxicol Pharmacol 2016;(81):489-99. DOI: 10.1016/j.yrtph.2016.09.014

For citation:Maksimov M.L., Danilova M.S., Shikaleva A.A., Zvegintzeva A.A. Using alternative nicotine products to reduce harm to patients not refusing nicotine consumption. Narrative review. Clinical review for general practice. 2024; 5 (11): 85–100 (In Russ.). DOI: 10.47407/kr2024.5.11.00521


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

Scopus
doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru